KPF
REGN icon

K2 Principal Fund’s Regeneron Pharmaceuticals REGN Stock Holding History

K2 Principal Fund’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-1,850
Closed -$646K – 309
2016
Q2 		$646K Buy
+1,850
New +$712K 0.09% 150

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

K2 Principal Fund's REGN Position: Q3 2016 in Review

K2 Principal Fund sold out of Regeneron Pharmaceuticals (REGN) in Q3 2016, closing a stake of 1,850 shares — an estimated $646K sold.

K2 Principal Fund first reported a position in REGN in Q2 2016 and held it in 1 quarter. The position peaked at $646K in Q2 2016. 553 funds tracked by Wall St. Rank hold REGN as of Q3 2016.

  • K2 Principal Fund reported no remaining Regeneron Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • K2 Principal Fund sold 1,850 Regeneron Pharmaceuticals shares in Q3 2016, an estimated $646K.
  • K2 Principal Fund first reported a position in Regeneron Pharmaceuticals in Q2 2016 and held it in 1 quarter.
  • K2 Principal Fund's Regeneron Pharmaceuticals position peaked at $646K in Q2 2016.
  • 553 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2016.

Based on K2 Principal Fund's 13F filing for Q3 2016, filed 15 Nov 2016.